AMD invests $20 million in Absci Corp., sparking retail interest and partnerships for drug discovery.

From StockTwits: 2025-01-10 08:44:14

AMD makes a $20 million investment in Absci Corp., marking its entry into life sciences. The partnership will integrate AMD’s high-performance computing capabilities with Absci’s AI-powered de novo antibody design models. Retail interest in Absci surged after the announcement, with message volume on Stocktwits soaring by 36,900%. Absci also announced a partnership with Owkin to speed up drug discovery for cancer and other conditions. Cathie Wood’s ARK Investment purchased over $1.9 million worth of Absci shares. KeyBanc lowered Absci’s price target to $5 but maintained an ‘Overweight’ rating, citing rebounding healthcare technology stocks. Absci reported $127.1 million in cash and equivalents as of September 30, 2024.



Read more at StockTwits: Small-Cap Biotech Absci Draws Heavy Attention On $20M AMD Investment Pledge, Retail’s Bullish Despite Pre-Market Dip